Advances in the development of vaccines against Neisseria meningitidis.
about
Enter B and W: two new meningococcal vaccine programmes launchedWill there ever be a universal Staphylococcus aureus vaccine?Clinical vaccine developmentMeningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal diseaseDesign and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen MoleculesStructure and mechanism of a molecular rheostat, an RNA thermometer that modulates immune evasion by Neisseria meningitidisHealth and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programmeAn evaluation of emerging vaccines for childhood meningococcal diseaseReview of meningococcal vaccines with updates on immunization in adultsInfections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyAntibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogensMucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motilityInvasive meningococcal disease in England: assessing disease burden through linkage of multiple national data sources.Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccineInhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat modelMenveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.Evolution of meningococcal carriage in serogroups X and Y before introduction of MenAfriVac in the health district of Kaya, Burkina Faso.AbsIDconvert: an absolute approach for converting genetic identifiers at different granularities.An expanded age range for meningococcal meningitis: molecular diagnostic evidence from population-based surveillance in Asia.Vibrio cholerae: lessons for mucosal vaccine design.Characterization and acceptor preference of a soluble meningococcal group C polysialyltransferase.Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive diseaseMeningococcal glycoconjugate vaccines.Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections.Immunological mechanisms of vaccination.The impact of aggregating serogroups in dynamic models of Neisseria meningitidis transmission.Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009.Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.Revealing the molecular signatures of host-pathogen interactions.Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria.Ion torrent personal genome machine sequencing for genomic typing of Neisseria meningitidis for rapid determination of multiple layers of typing informationFast and accurate dynamic estimation of field effectiveness of meningococcal vaccines
P2860
Q26775667-C481FA38-D920-415A-BFFA-D9B2B34409AFQ26824837-F5C506F6-1931-45A5-8D18-7A4A434EE525Q27013155-DDE8FC08-AED2-4F8C-A7CF-56D9E3EDE496Q27028161-49B350A9-E954-41C6-BD48-C665834042E4Q27675010-98717517-18C0-4BE7-8CAA-DE333320827EQ27715823-8ECD0A7B-DDA1-4DEE-AC8C-3DBF68C28D13Q28391723-B91F7BD3-FB74-42BD-BA7C-728BFF42D7A2Q28741833-04B0B86D-5F9D-4FAB-868F-101E73AAF2A7Q28828692-7CCE2543-485F-4905-BFE8-919A508C8D5CQ28972389-1DF57197-14F9-4208-B98D-78B99C102168Q30415823-3397934F-07BE-46B7-BC2D-631C532EEB26Q30496874-14845DDA-0D1F-425B-8D82-0549BFF19FC5Q31029757-6CA9F9CE-2DC0-4AE8-834F-2663E97294B5Q33600936-6F688F4F-0D67-44C2-8BC2-26186951D542Q33602953-66A9AD60-BFAC-4B91-B436-D23286DB259AQ34155231-7DC1BE11-577B-4C3C-BDF2-463B08BAF30AQ34290891-1BE0A798-2E0D-4CB5-A971-453470B8D316Q34291176-143327BC-7442-4A89-B260-F8746B81AAF4Q34320259-464AB51E-B3DC-4EA4-9E0C-6DEA4C8A5EAEQ34363122-D8CF480F-3355-4335-A4E5-63A1A6941652Q34411163-6B8721BD-2F25-4C82-9269-4E4574F5146FQ34481220-64F42C0D-C0E1-4B4D-8DB7-9C8A62B535D1Q34562952-47A5DD82-2488-439E-B7D2-8C09DB353AA8Q34740881-FCF13B17-C2C2-4711-B3F3-4EBAAAF77163Q34955474-EBE05A7C-98C8-4692-8A26-081AA5D281F4Q35187182-7A3CE3F8-ED73-453D-9368-C94282E69B7EQ35194824-905FD163-39B3-4C64-8686-8B8A762CE024Q35290278-7A3D86D0-A45E-431E-AD7F-AFD9E48AB49FQ35659533-540CF940-F209-4D7F-9A14-2052EFAF4397Q35724206-C095A4DF-F539-4071-A0EA-F980096F8F73Q35778492-83840C69-8E13-4F79-BA9C-2DAE3FC48E67Q35799561-614D22CC-3D9D-4F59-B0C5-F466E6CF101CQ35845900-1EF38AD8-7505-4398-BA2B-94F6D717DD33Q35887131-EEA66214-3C90-4052-B7BA-77E731AACDBAQ35905785-74BFA61A-DE26-4552-AD19-BB999548C144Q35940728-D0272E8C-4230-43CF-9915-6C5B5CD41388Q35989852-67A4BD15-D4E2-433B-AA3A-B427C2674685Q36016022-3E47A52D-2F81-409E-A408-A809E425C07AQ36022991-D4DE9927-3A5E-44CB-81CE-F027F733DA25Q36065267-3F64E92D-A94F-4757-8644-C847BEEDDE93
P2860
Advances in the development of vaccines against Neisseria meningitidis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Advances in the development of vaccines against Neisseria meningitidis.
@en
Advances in the development of vaccines against Neisseria meningitidis.
@nl
type
label
Advances in the development of vaccines against Neisseria meningitidis.
@en
Advances in the development of vaccines against Neisseria meningitidis.
@nl
prefLabel
Advances in the development of vaccines against Neisseria meningitidis.
@en
Advances in the development of vaccines against Neisseria meningitidis.
@nl
P356
P1476
Advances in the development of vaccines against Neisseria meningitidis.
@en
P2093
George M Carlone
Lionel K K Tan
P304
P356
10.1056/NEJMRA0906357
P407
P50
P577
2010-04-01T00:00:00Z